Abstract Details

Title Relative Contribution of Migraine with Aura to Cardiovascular Disease Occurrence in Women

Topic Headache

Presentation(s) S40 - (-)

Poster/Presentation
Number 001

Background Migraine with aura has been consistently linked with increased risk of ischemic stroke. There is emerging evidence that MA is also a maker for increased CVD risk. However, the relative contribution of MA to the occurrence of CVD in relation with other major vascular risk factors remains unclear.

Objective

Design/Methods Prospective cohort study of 27,860 women aged ?45 who were participating in the Women's Health Study, were free of CVD at baseline, and for whom we had self-reported information on migraine and lipid measurements. Women were followed for medical record confirmed major CVD (nonfatal myocardial infarction, nonfatal stroke, or CVD death). We used multivariable standardization models to evaluate the contribution of MA to CVD risk relative to other major vascular risk factors.

Results At baseline, 5130 reported migraine of whom 1435 (40%) reported MA. During 15 years of follow-up, 1030 major CVD events were confirmed (overall incidence rate [IR] 2.4 per 1000 women per year (95% confidence interval 2.3-2.6). After having a systolic blood pressure ?180mgHg adjusted IR=9.8 (6.9-13.9), MA was the second strongest single contributor to major CVD risk (IR=7.9; 6.2-10.0) followed by diabetes (IR=7.1; 5.6-8.9), family history of premature myocardial infarction (IR=5.4; 4.5-6.5), current smoking (IR=5.4; 4.6-6.4), and body mass index ?35 kg/m2 (IR=5.3; 4.0-7.2). In relation to the Framingham risk score for coronary heart disease, women with MA had 10 year risk of major CVD comparable with the 2-4% Framingham risk group while women in the ?10% risk group had highest major CVD risk (IR=16.6; 13.1-21.0).

Conclusions While the combination of traditional vascular risk factors still shows the strongest contribution to CVD occurrence, MA is a strong relative contributor to increased risk of CVD events.

Authors/Disclosures
Tobias Kurth, MD, ScD, FAAN (Charité - Universitätsmedizin Berlin) PRESENTER	Dr. Kurth has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for TotalEnergies. Dr. Kurth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly & Company. Dr. Kurth has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for BMJ. Dr. Kurth has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Frontiers. The institution of Dr. Kurth has received research support from German Joint Committee. The institution of Dr. Kurth has received research support from Ministry of Health.
	No disclosure on file
	No disclosure on file
Philippe Picaut	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��